NYSE - Delayed Quote USD
Charles River Laboratories International, Inc. (CRL)
185.00 +2.66 (+1.46%)
At close: June 18 at 4:00:02 PM EDT
185.37 +0.37 (+0.20%)
After hours: June 18 at 5:05:00 PM EDT
Trade CRL on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreChart Range Bar
Loading chart for CRL
- Previous Close
182.34 - Open
183.70 - Bid 178.00 x 30000
- Ask 204.46 x 40000
- Day's Range
182.00 - 186.18 - 52 Week Range
144.26 - 228.88 - Volume
1,170,070 - Avg. Volume
865,937 - Market Cap (intraday)
8.911B - Beta (5Y Monthly) 1.45
- PE Ratio (TTM)
-- - EPS (TTM)
-3.72 - Earnings Date (est.) Aug 5, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
215.33
Recent News
View More
Performance Overview
Trailing total returns as of 6/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
CRL
7.26%
S&P 500 (^GSPC)
9.57%
1-Year Return
CRL
27.33%
S&P 500 (^GSPC)
25.41%
3-Year Return
CRL
11.90%
S&P 500 (^GSPC)
70.10%
5-Year Return
CRL
47.70%
S&P 500 (^GSPC)
80.02%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 6/18/2026
Market Cap
8.91B
Enterprise Value
11.78B
Trailing P/E
--
Forward P/E
16.61
PEG Ratio (5yr expected)
0.12
Price/Sales (ttm)
2.26
Price/Book (mrq)
3.03
Enterprise Value/Revenue
2.92
Enterprise Value/EBITDA
40.53
Financial Highlights
Profitability and Income Statement
Profit Margin
-4.59%
Return on Assets (ttm)
4.26%
Return on Equity (ttm)
-5.87%
Revenue (ttm)
4.03B
Net Income Avi to Common (ttm)
-184.65M
Diluted EPS (ttm)
-3.72
Balance Sheet and Cash Flow
Total Cash (mrq)
191.83M
Total Debt/Equity (mrq)
102.55%
Levered Free Cash Flow (ttm)
510.02M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
185.00
+1.46%
Mkt Cap 8.911B
Industry Diagnostics & Research
1,144.84
+1.36%
Mkt Cap 23.134B
Industry Diagnostics & Research
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View MoreCharles River Earnings: Near‑Term Headwinds Mask Improving Demand and Margin Outlook
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company’s research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
RatingPrice TargetCharles River Earnings: Near‑Term Headwinds Mask Improving Demand and Margin Outlook
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company’s research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
RatingPrice TargetCharles River Earnings: Near‑Term Headwinds Mask Improving Demand and Margin Outlook
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company’s research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
RatingPrice TargetCharles River: Downgrading Moat Rating to None and Decreasing Fair Value Estimate to $135
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company’s research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
RatingPrice Target